BIOGNOSYS
13.4.2021 13:17:13 CEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California. The agreement leverages Biognosys’ expertise in unbiased biomarker discovery technologies and solutions with Siemens Healthineers’ biomarker assay development, lab testing, and commercialization capabilities.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “With this agreement we can enable our biopharmaceutical customers to use the power of our proprietary discovery proteomics solution for novel biomarker identification and bring these biomarkers into clinical applications with Siemens Healthineers’ diagnostic assay development expertise.”
Using Biognosys’ proprietary Hyper Reaction Monitoring (HRMTM ) mass spectrometry technology, thousands of proteins may be quantified simultaneously from a broad range of clinical sample types. HRM enables an unmatched depth of proteome coverage with reproducible and precise quantification to identify the most promising, actionable biomarkers to support clinical decision making. This discovery proteomics solution can be applied with high throughput in large-scale studies involving thousands of samples.
The strategic agreement enables discovery of novel biomarkers via the HRM technology followed by translation into validated biomarker assays for potential clinical applications. This may include clinical trials usage and In Vitro Diagnostics development programs.
Sebastian Kronmueller, Head of Siemens Healthcare Laboratory in California, commented: “We are excited about this relationship with Biognosys because their expertise and unique biomarker discovery capabilities are very complementary to our end-to-end diagnostic solutions for our biopharmaceutical customers.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company’s proprietary solutions provide a multi-dimensional view of protein expression, function, and structure in all major biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading, precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005039/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13.8.2026 16:05:00 CEST | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813362140/en/ Laura Shannon joins Clinilabs as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive
Resurgens Technology Partners Invests in Qarma to Advance the Future of Quality and Compliance13.8.2026 15:00:00 CEST | Press release
Partnership brings together Resurgens' software investing expertise and Qarma’s leading quality and compliance platform to accelerate product innovation and expand its reach across North America, Europe, and Asia Resurgens Technology Partners (“Resurgens”), a software-focused private equity firm, today announced its partnership with Qarma, a leading global provider of AI-powered quality and compliance software for brands, retailers, and manufacturers managing complex, global supply chains. Qarma has built a platform that combines best-practice quality and compliance with hands-on execution where it matters most, on the factory floor. Qarma will continue to be led by its Co-founders, CEO Jacob Nedergaard and CTO Søren Mønsted. Founded in 2016, Qarma serves customers across industries, including furniture and home, apparel, consumer goods, and electronics. Its platform connects quality and compliance teams, sourcing professionals, suppliers, and inspectors. Over the past decade, Qarma ha
Tecnotree Signs 17.5 Million USD Multi-Year Agreement with Existing Communications Service Provider in the Americas13.8.2026 14:04:00 CEST | Press release
Tecnotree, a global provider of 5g and AI-native digital business support systems (BSS) and digital transformation solutions for communications service providers, announced the signing of a new multi-year, multi-region agreement with an existing communications service provider in the Americas. The agreement reflects Tecnotree’s continued focus on expanding long-term customer relationships through its 5g AI-native digital platforms and services enabling communications service providers to modernize business operations, accelerate service innovation, and enhance customer experiences, Tecnotree continues to support the evolving digital transformation priorities of operators worldwide. “The Americas remains an important market for Tecnotree, where the company continues to support communications service providers with solutions that simplify operations, enable business agility, and create sustainable value through next-generation digital services,” said Padma Ravichander, CEO Tecnotree. Abo
Vantage Data Centers and Nebius Expand UK AI Infrastructure with First Deployment in South Wales AI Growth Zone13.8.2026 14:00:00 CEST | Press release
Deployment will add high-density NVIDIA-powered AI capacity at Vantage’s Newport campus, supporting the UK’s ambition to scale domestic AI compute and reinforcing South Wales as a strategic digital infrastructure hub Vantage Data Centers, a leading global provider of hyperscale data center campuses, and Nebius (Nasdaq: NBIS), the AI cloud company, today announced an agreement to deploy high-density, NVIDIA-powered AI infrastructure at Vantage’s CWL1 campus in Newport, Wales. The deployment represents the first announced commercial capacity commitment in the South Wales AI Growth Zone and will support growing UK demand for domestic AI compute capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813253918/en/ CWL13 data center at Vantage’s Newport, Wales, campus. Under the agreement, Nebius will lease high-density capacity at CWL1 to support AI training, inference, agentic AI and enterprise AI workloads, serving enterpr
SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results13.8.2026 12:30:00 CEST | Press release
Restructuring Complete, Growth Reaccelerates: Q2 Revenue Up 13%, Net Income Attributable to SBC Medical Up 335%, Adjusted EBITDA1 Up 32% Year-over-Year. AI-Enabled Service Enhancements Drive Successful Fee Increases, Positioning the Business for Accelerated Network Expansion SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026). Second Quarter 2026 Financial Highlights Total revenues were $49 million, an increase of 13% year-over-year. Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom